MoonLake Immunotherapeutics (MLTX) EBIT (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly EBIT of -$70.0 million for Q1 2026, down 47.47% year-over-year from -$133.3 million in Q1 2025, and down 7.37% quarter-over-quarter from -$65.2 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) EBIT (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' EBIT history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.
- In Q1 2026, EBIT fell 47.47% year-over-year to -$70.0 million; the TTM figure through Mar 2026 stood at -$267.4 million (down 56.58% YoY), while the FY2025 annual figure was -$244.8 million, down 71.1% from the prior year.
- EBIT for Q1 2026 stood at -$70.0 million, down from -$65.2 million in the prior quarter.
- The five-year high for EBIT was -$12.9 million in Q1 2023, with the low at -$71.4 million in Q3 2025.
- The 5-year median for EBIT is -$19.8 million (2024), against an average of -$33.9 million.
- Peak annual rise in EBIT reached 68.84% in 2022, while the deepest fall reached 16840.81% in 2022.
- MoonLake Immunotherapeutics' EBIT stood at -$16.7 million in 2022, then rose by 9.99% to -$15.0 million in 2023, then sank by 229.9% to -$49.6 million in 2024, then sank by 31.54% to -$65.2 million in 2025, then declined by 7.37% to -$70.0 million in 2026.
- Business Quant data shows MLTX's EBIT at -$70.0 million in Q1 2026, -$65.2 million in Q4 2025, and -$71.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -61.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.66 Mn |
| Mar 31, 2026 | -70.02 Mn |
| Dec 31, 2025 | -65.22 Mn |
| Sep 30, 2025 | -71.43 Mn |
| Jun 30, 2025 | -60.70 Mn |
| Mar 31, 2025 | -47.49 Mn |
| Dec 31, 2024 | -49.58 Mn |
| Sep 30, 2024 | -43.11 Mn |
| Jun 30, 2024 | -30.58 Mn |
| Mar 31, 2024 | -19.82 Mn |
| Dec 31, 2023 | -15.03 Mn |
| Sep 30, 2023 | -12.98 Mn |
| Jun 30, 2023 | -13.19 Mn |
| Mar 31, 2023 | -12.93 Mn |
| Dec 31, 2022 | -16.70 Mn |
| Sep 30, 2022 | -14.77 Mn |
| Jun 30, 2022 | -17.65 Mn |
| Mar 31, 2022 | -15.94 Mn |
| Dec 31, 2021 | -53.58 Mn |
| Sep 30, 2021 | -6.27 Mn |